Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: A systematic review and network meta-analysis

To evaluate the effectiveness of glucagon-like peptide-1 receptor agonists (glp-1 ras) on weight reduction in patients with type 2 diabetes mellitus (type 2 dm),a network meta-analysis was conducted. medline,embase,cochrane library,and clinicaltrials.gov were searched from 1950 to october 2013. randomized controlled trials (rcts) involving glp-1 ras were included if they provided information on body weight. a total of 51 rcts were included and 17521 participants were enrolled. the mean duration of 51 rcts was 31 weeks. exenatide 10 g twice daily (ex10bid) reduced weight compared with exenatide 5 g twice daily (ex5bid),liraglutide 0.6 mg once daily (lir0.6qd),liraglutide - 1.2 mg once daily (lir1.2qd),and placebo treatment,with mean differences of -1.07 kg (95% ci: -2.41,-0.02),-2.38 kg (95% ci: -3.71,-1.06),-1.62 kg (95% ci: -2.79,-0.43),and -1.92 kg (95% ci: -2.61,-1.24),respectively. reductions of weight treated with liraglutide - 1.8 mg once daily (lir1.8qd) reach statistical significance (-1.43 kg (95% ci: -2.73,-0.15)) versus lir1.2qd and (-0.98 kg (95% ci: -1.94,-0.02)) versus placebo. network meta-analysis found that ex10bid,lir1.8qd,and ex2qw obtained a higher proportion of patients with weight loss than other traditional hypoglycemic agents. our results suggest glp-1 ras are promising candidates for weight control in comparison with traditional hypoglycemic drugs,and ex10bid,lir1.8qd,and ex2qw rank the top three drugs. © 2015 feng sun et al.